<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 21 Mar 2025 01:19:25 +0000</lastBuildDate><item><title>Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology</title><link>https://www.drugdiscoverytrends.com/flatiron-health-sees-shift-from-what-if-to-what-is-in-real-world-evidence-in-oncology/</link><description>Flatiron Health is redefining cancer care by transitioning from skepticism about AI in healthcare to demonstrating real-world applications and outcomes in oncology. With a focus on harnessing data effectively post-ChatGPT, the company is advancing its role in evidence generation for cancer treatment.</description><pubDate>Wed, 12 Feb 2025 03:39:41 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>Rosnilimab, a new treatment targeting the PD-1 pathway, has shown promise in a phase 2b trial for rheumatoid arthritis by aiming to reset the immune system for better long-term remission. Unlike traditional therapies that often leave patients without sustained relief, rosnilimab offers a novel approach through the selective depletion of pathogenic cells.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>COTA Healthcare announces AI milestone in real-world oncology data</title><link>https://www.drugdiscoverytrends.com/cota-healthcare-announces-ai-milestone-in-real-world-oncology-data/</link><description>COTA Healthcare has announced a breakthrough in real-world oncology data with the launch of a generative AI platform that enables accurate and profitable large-scale curation. This innovation signifies a significant advancement from earlier efforts to automate the challenging process of RWD abstraction in the oncology field.</description><pubDate>Wed, 26 Feb 2025 19:00:13 +0000</pubDate></item><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug</title><link>https://www.biospace.com/drug-development/pfizer-arvinas-post-mixed-late-stage-breast-cancer-data-for-closely-watched-protac-drug</link><description>Vepdegestrant’s mixed trial results—stalling on broad progression-free survival but showing promise in a niche patient group—sparked a 43% plunge in Arvinas’ stock, with analysts casting doubt on the drug's long-term viability. While no new deals were announced, the setback raises questions about the company’s ability to attract future partnerships or advance the drug’s commercial prospects.</description><pubDate>Tue, 11 Mar 2025 14:08:28 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Agenus CMO touts immunotherapy advances on The Top Line</title><link>https://www.fiercebiotech.com/sponsored/agenus-cmo-touts-immunotherapy-advances-top-line</link><description>Agenus Chief Marketing Officer highlighted significant advancements in their immunotherapy pipeline during a recent appearance on The Top Line, emphasizing the company's commitment to innovative cancer treatments. The discussion included insights into upcoming clinical trials and potential partnerships aimed at enhancing their therapeutic offerings in the oncology space.</description><pubDate>Tue, 11 Mar 2025 17:26:30 +0000</pubDate></item><item><title>Advancing the Future of Biomarker-Driven Immunotherapy</title><link>https://www.fiercebiotech.com/premium/webinar/1369042</link><description>The upcoming webinar will delve into the DUTRENEO trial's findings on predictive biomarkers for neoadjuvant therapy in muscle-invasive bladder cancer, highlighting the potential of spatial biomarkers and multi-omics approaches. It aims to address challenges in patient stratification for immune checkpoint inhibitors and discuss implications for future clinical trial designs.</description><pubDate>Fri, 14 Mar 2025 17:43:32 +0000</pubDate></item><item><title>How Proscia is using AI embeddings to transform drug discovery in pathology</title><link>https://www.drugdiscoverytrends.com/how-proscia-is-using-ai-embeddings-to-transform-drug-discovery-in-pathology/</link><description>Proscia has leveraged AI-powered pathology analysis to revive a lung cancer drug candidate by identifying patients who would benefit from the treatment through advanced machine learning algorithms. This innovative approach bridges the gap in drug discovery by distinguishing between responders and non-responders, showcasing the transformative potential of digital pathology.</description><pubDate>Mon, 17 Mar 2025 20:43:21 +0000</pubDate></item><item><title>Sofinnova’s latest biotech fund sprouts three new startups</title><link>https://www.biopharmadive.com/news/sofinnova-fund-startups-bioclec-signadori-forth/742816/</link><description>Sofinnova is investing in startups focused on developing treatments for fibrosis, cancer, and Alzheimer’s as part of its broader "pan-European" strategy. This initiative aims to support innovative healthcare solutions across Europe.</description><pubDate>Tue, 18 Mar 2025 15:50:25 +0000</pubDate></item><item><title>GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors</title><link>https://www.biospace.com/business/glp-1-drug-boom-recalls-the-rise-of-pd-1-checkpoint-inhibitors</link><description>The rapid rise of GLP-1 weight loss medications mirrors the initial success of PD-1 inhibitors; however, distinct market dynamics indicate that the outcomes for these two classes of drugs may differ significantly. As GLP-1 drugs gain popularity, industry stakeholders are keenly observing how their market trajectories unfold compared to immuno-oncology therapies.</description><pubDate>Wed, 19 Mar 2025 06:11:00 +0000</pubDate></item><item><title>Insight and insitro partner on AI model to seek ocular biomarkers</title><link>https://www.pharmaceutical-technology.com/news/insight-insitro-ai-model/</link><description>Insight Health Data Research Hub and insitro have partnered to create an AI foundation model aimed at identifying ocular biomarkers. This collaboration seeks to enhance the understanding and diagnosis of eye-related health conditions through advanced technology.</description><pubDate>Wed, 19 Mar 2025 10:47:43 +0000</pubDate></item><item><title>Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond</title><link>https://www.biospace.com/deals/black-diamond-nabs-solid-tumor-asset-in-up-to-780m-deal-with-servier</link><description>A French pharmaceutical company has acquired Black Diamond's de-prioritized molecule intended for non-small cell lung cancers with specific mutations, which had seen its development halted to cut costs. This strategic acquisition aims to revitalize the drug's potential in the oncology market.</description><pubDate>Wed, 19 Mar 2025 14:24:52 +0000</pubDate></item><item><title>Blood cancers dominate CAR-T pipeline</title><link>https://www.pharmaceutical-technology.com/analyst-comment/blood-cancers-car-t-pipeline/</link><description>Gilead's Yescarta and Immuneel Therapeutics' Qartemi are among the 13 CAR-T therapeutics that have successfully gained regulatory approval. These advancements highlight significant progress in the development of innovative cancer treatments.</description><pubDate>Thu, 20 Mar 2025 08:11:08 +0000</pubDate></item><item><title>Oxford BioTherapeutics and Roche link on antibody cancer treatments</title><link>https://www.pharmaceutical-technology.com/news/oxford-roche-cancer-treatments/</link><description>OBT has announced a multi-year partnership with Roche aimed at discovering innovative antibody-based therapeutics for cancer treatment. This collaboration seeks to leverage both companies' expertise to advance new cancer therapies.</description><pubDate>Thu, 20 Mar 2025 08:46:53 +0000</pubDate></item><item><title>Sanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleter</title><link>https://endpts.com/sanofi-to-pay-600m-upfront-for-dren-bios-bispecific-b-cell-depleter/</link><description>Sanofi is acquiring a B cell-depleting antibody from Dren Bio for $600 million, aimed at treating cancer and autoimmune diseases. This strategic move underscores Sanofi's commitment to expanding its oncology and immunology portfolio.</description><pubDate>Thu, 20 Mar 2025 10:31:29 +0000</pubDate></item><item><title>Gantenerumab 'shows sign of preventing Alzheimer's dementia'</title><link>https://pharmaphorum.com/news/gantenerumab-shows-sign-preventing-alzheimers-dementia</link><description>A new study indicates that early intervention targeting amyloid in the brains of individuals with inherited Alzheimer's may postpone the onset of symptoms. However, skepticism remains among some experts regarding the efficacy of this approach.</description><pubDate>Thu, 20 Mar 2025 11:13:57 +0000</pubDate></item><item><title>Roche’s discontinued Alzheimer’s drug shows signs of preventing onset</title><link>https://www.pharmaceutical-technology.com/news/roche-alzheimer-drug-could-prevent-onset/</link><description>A recent OLE study revealed that Roche's gantenerumab significantly reduced the risk of developing Alzheimer's symptoms by 50%. This promising result could lead to advancements in treatment options for those at risk of the disease.</description><pubDate>Thu, 20 Mar 2025 11:43:46 +0000</pubDate></item><item><title>Servier and Black Diamond sign deal for solid tumours therapy</title><link>https://www.pharmaceutical-technology.com/news/servier-black-diamond-deal/</link><description>Servier and Black Diamond Therapeutics have entered into a licensing agreement for the targeted therapy BDTX-4933, designed to treat solid tumors. This partnership aims to enhance the development and accessibility of innovative cancer treatments.</description><pubDate>Thu, 20 Mar 2025 13:42:55 +0000</pubDate></item><item><title>Illumina's CEO evolves strategy with multiomics push</title><link>https://endpts.com/illuminas-ceo-evolves-strategy-with-multiomics-push/</link><description>Illumina CEO Jacob Thaysen showcased the company's innovative campus design, featuring a staircase inspired by a DNA strand, during a recent event in San Diego. This architectural flourish reflects Illumina's commitment to advancing genetics and biotechnology.</description><pubDate>Thu, 20 Mar 2025 14:30:21 +0000</pubDate></item><item><title>Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding</title><link>https://endpts.com/elevation-oncology-stops-work-on-adc-lays-off-workers-astrazenecas-cepi-funding/</link><description>Elevation Oncology has decided to discontinue its antibody-drug conjugate (ADC) program and has laid off 70% of its workforce as part of a strategic shift. The company is pivoting its focus towards other therapeutic avenues to enhance its portfolio.</description><pubDate>Thu, 20 Mar 2025 15:10:58 +0000</pubDate></item><item><title>Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease</title><link>https://www.biopharmadive.com/news/sanofi-dren-deal-bispecific-myeloid-cell-engager-autoimmune/743041/</link><description>Sanofi has acquired startup Dren Bio to gain access to its innovative myeloid cell engager, which is designed to compete with various treatments aimed at resetting immune systems for individuals with inflammatory conditions. This strategic move positions Sanofi to enhance its portfolio in the growing field of immunotherapy.</description><pubDate>Thu, 20 Mar 2025 15:20:00 +0000</pubDate></item></channel></rss>